SCHEMBL4306240

SCHEMBL4306240

CCc1cc(Br)ccc1OC(F)F

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.38
HPGD P15428 2/20 0.37
TSHR P16473 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
LMNA P02545 3/20 0.37
ATM Q13315 1/20 0.37
KDM4E B2RXH2 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
GLA P06280 1/20 0.36
SLC6A4 P31645 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
PTGER1 P34995 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18151138 0.84 L3MBTL1 (0.38) L3MBTL1PTGDR2SMN1; SMN2LMNAKDM4E
SCHEMBL3991129 0.84 ALDH1A1 (0.41) PTGDR2TSHRSMN1; SMN2LMNAATM
SCHEMBL16959585 0.82 PTGDR2 (0.53) L3MBTL1PTGDR2SMN1; SMN2LMNATDP1
SCHEMBL27779818 0.81 TAAR1 (0.41) L3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL3359233 0.81 L3MBTL1 (0.36) L3MBTL1PTGDR2SMN1; SMN2LMNAKDM4E
SCHEMBL4312392 0.80 KDM4E (0.41) L3MBTL1HPGDLMNAKDM4ETDP1
SCHEMBL15108891 0.80 NTRK1 (0.42) HPGDSMN1; SMN2KDM4ESLC6A4KMT2A
SCHEMBL4308482 0.80 L3MBTL1 (0.42) L3MBTL1TSHRSMN1; SMN2LMNAKDM4E
SCHEMBL4304316 0.80 ACACB (0.41) L3MBTL1SMN1; SMN2PTGER1ALDH1A1
SCHEMBL3357880 0.79 USP28 (0.40) L3MBTL1PTGDR2SMN1; SMN2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180086737-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-03-29 US disclosed
US-20160304496-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 US disclosed
CN-101641335-A Amino-5-[substituted-4-(difluoromethoxy)phenyl]-5- phenylimidazolone compounds as ss-secretase inhibitors WYETH CORP US 2010-02-03 CN disclosed
EP-2137161-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2009-12-30 EP disclosed
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS WYETH (US) 2009-02-12 US disclosed
WO-2008115552-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS WYETH (US) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304496-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING TNF, CD40, TNFRSF1A L3MBTL1 4393/4885PTGDR2 437/4885HPGD 276/4885
US-20180086737-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING TNF, CD40, TNFRSF1A L3MBTL1 4393/4885PTGDR2 437/4885HPGD 276/4885
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS BACE1, BACE2, APP L3MBTL1 3592/4885PTGDR2 4586/4885HPGD 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.